Find drug development pipeline and deal Updates information

Lead Product(s): ONCOS-102, Cisplatin, Pemetrexed

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

Preliminary data show a numerical advantage in Progression Free Survival in ONCOS-102 treated patients.

Lead Product(s): Apricoxib

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: IOVaxis Therapeutics

Deal Size: $100.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 08, 2020

Details:

Under the agreement, IOVaxis and Targovax will jointly define a development plan in the territory, and IOVaxis will be responsible for all local regulatory filings and will sponsor clinical trials.